Chronic liver inflammation modifies DNA methylation at the precancerous stage of murine hepatocarcinogenesis

Oncotarget

Volumn 6, Issue 13, 2015, Pages 11047-11060

  Stoyanov, Evgeniy ^a   Ludwig, Guy ^b   Mizrahi, Lina ^a   Olam, Devorah ^a   Schnitzer Perlman, Temima ^a   Tasika, Elena ^c   Sass, Gabriele ^c   Tiegs, Gisa ^c   Jiang, Yong ^d   Nie, Ting ^d   Kohler, James ^d   Schinazi, Raymond F ^d   Vertino, Paula M ^d   Cedar, Howard ^b   Galun, Eithan ^a   Goldenberg, Daniel ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 hydroxymethylcytosine; DNA methylation; Hepatocellular carcinoma; Mdr2 (Abcb4); mtDNA deletion

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; 5 METHYLCYTOSINE; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; SYNAPTOPODIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; P-GLYCOPROTEIN 2;

AGE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BMP8B GENE; CANCER STAGING; CELL FRACTIONATION; CHRONIC HEPATITIS; CONTROLLED STUDY; CPG ISLAND; CYBA GENE; DISEASE COURSE; DNA HYBRIDIZATION; DNA METHYLATION; DOWN REGULATION; FAM65B GENE; GENE; GENE DELETION; GENE EXPRESSION REGULATION; IL1R1 GENE; IMMUNOPRECIPITATION; LIVER CARCINOGENESIS; LIVER CELL; LIVER LEVEL; LRRC16A GENE; MALE; MMP23 GENE; MOUSE; MOUSE MUTANT; NONHUMAN; PRECANCER; SRD5A2 GENE; SYNPO GENE; UPREGULATION; ANIMAL; CARCINOMA, HEPATOCELLULAR; CELL CULTURE; CHRONIC DISEASE; COMPLICATION; GENE EXPRESSION PROFILING; GENETICS; HUMAN; INFLAMMATION; KNOCKOUT MOUSE; LIVER; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PRECANCEROUS CONDITIONS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELLS, CULTURED; CHRONIC DISEASE; CPG ISLANDS; DNA METHYLATION; GENE EXPRESSION PROFILING; HEPATOCYTES; HUMANS; INFLAMMATION; LIVER; LIVER NEOPLASMS; MICE; MICE, KNOCKOUT; P-GLYCOPROTEINS; PRECANCEROUS CONDITIONS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84929629987     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3567     Document Type: Article

References (64)

1. Stauffer JK, Scarzello AJ, Jiang Q and Wiltrout RH. Chronic inflammation, immune escape, and oncogenesis in the liver: a unique neighborhood for novel intersections. Hepatology. 2012; 56(4):1567-1574.
2. Baylin SB. Tying it all together: epigenetics, genetics, cell cycle, and cancer. Science. 1997; 277(5334):1948-1949.
3. Keshet I, Schlesinger Y, Farkash S, Rand E, Hecht M, Segal E, Pikarski E, Young RA, Niveleau A, Cedar H and Simon I. Evidence for an instructive mechanism of de novo methylation in cancer cells. Nat Genet. 2006; 38(2):149-153.
4. McCabe MT, Brandes JC and Vertino PM. Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res. 2009; 15(12):3927-3937.
5. Yamada Y, Jackson-Grusby L, Linhart H, Meissner A, Eden A, Lin H and Jaenisch R. Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis. Proc Natl Acad Sci U S A. 2005; 102(38):13580-13585.
6. Nishida N, Nagasaka T, Nishimura T, Ikai I, Boland CR and Goel A. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology. 2008; 47(3):908-918.
7. Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA, Schroeder I, Factor VM and Thorgeirsson SS. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest. 2007; 117(9):2713-2722.
8. Hernandez-Vargas H, Lambert MP, Le Calvez-Kelm F, Gouysse G, McKay-Chopin S, Tavtigian SV, Scoazec JY and Herceg Z. Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors. PLoS One. 2010; 5(3):e9749.
9. Stefanska B, Huang J, Bhattacharyya B, Suderman M, Hallett M, Han ZG and Szyf M. Definition of the landscape of promoter DNA hypomethylation in liver cancer. Cancer Res. 2011; 71(17):5891-5903.
10. Neumann O, Kesselmeier M, Geffers R, Pellegrino R, Radlwimmer B, Hoffmann K, Ehemann V, Schemmer P, Schirmacher P, Lorenzo Bermejo J and Longerich T. Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors. Hepatology. 2012; 56(5):1817-1827.
11. Hahn MA, Hahn T, Lee DH, Esworthy RS, Kim BW, Riggs AD, Chu FF and Pfeifer GP. Methylation of polycomb target genes in intestinal cancer is mediated by inflammation. Cancer Res. 2008; 68(24):10280-10289.
12. Kanai Y. Genome-wide DNA methylation profiles in precancerous conditions and cancers. Cancer Sci. 2010; 101(1):36-45.
13. Herceg Z and Paliwal A. Epigenetic mechanisms in hepatocellular carcinoma: how environmental factors influence the epigenome. Mutat Res. 2011; 727(3):55-61.
14. Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ and Kang GH. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol. 2003; 163(4):1371-1378.
15. Nagashio R, Arai E, Ojima H, Kosuge T, Kondo Y and Kanai Y. Carcinogenetic risk estimation based on quantification of DNA methylation levels in liver tissue at the precancerous stage. Int J Cancer. 2011; 129(5):1170-1179.
16. Nishida N, Kudo M, Nagasaka T, Ikai I and Goel A. Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. Hepatology. 2012; 56(3):994-1003.
17. Ammerpohl O, Pratschke J, Schafmayer C, Haake A, Faber W, von Kampen O, Brosch M, Sipos B, von Schonfels W, Balschun K, Rocken C, Arlt A, Schniewind B, et al. Distinct DNA methylation patterns in cirrhotic liver and hepatocellular carcinoma. Int J Cancer. 2012; 130(6):1319-1328.
18. Mauad TH, van Nieuwkerk CM, Dingemans KP, Smit JJ, Schinkel AH, Notenboom RG, van den Bergh Weerman MA, Verkruisen RP, Groen AK, Oude Elferink RPJ, van der Valk MA, Borst P and Offerhaus GJA. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol. 1994; 145(5):1237-1245.
19. Fickert P, Fuchsbichler A, Wagner M, Zollner G, Kaser A, Tilg H, Krause R, Lammert F, Langner C, Zatloukal K, Marschall HU, Denk H and Trauner M. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology. 2004; 127(1):261-274.
20. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E and Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004; 431(7007):461-466.
21. Katzenellenbogen M, Pappo O, Barash H, Klopstock N, Mizrahi L, Olam D, Jacob-Hirsch J, Amariglio N, Rechavi G, Mitchell LA, Kohen R, Domany E, Galun E, et al. Multiple adaptive mechanisms to chronic liver disease revealed at early stages of liver carcinogenesis in the Mdr2- knockout mice. Cancer Res. 2006; 66(8):4001-4010.
22. Potikha T, Stoyanov E, Pappo O, Frolov A, Mizrahi L, Olam D, Shnitzer-Perlman T, Weiss I, Barashi N, Peled A, Sass G, Tiegs G, Poirier F, et al. Interstrain differences in chronic hepatitis and tumor development in a murine model of inflammation-mediated hepatocarcinogenesis. Hepatology. 2013; 58(1):192-204.
23. Barashi N, Weiss ID, Wald O, Wald H, Beider K, Abraham M, Klein S, Goldenberg D, Axelrod J, Pikarsky E, Abramovitch R, Zeira E, Galun E, et al. Inflammationinduced hepatocellular carcinoma is dependent on CCR5 in mice. Hepatology. 2013; 58(3):1021-1030.
24. Katzenellenbogen M, Mizrahi L, Pappo O, Klopstock N, Olam D, Jacob-Hirsch J, Amariglio N, Rechavi G, Domany E, Galun E and Goldenberg D. Molecular mechanisms of liver carcinogenesis in the Mdr2-knockout mice. Mol Cancer Res. 2007; 5(11):1159-1170.
25. Ella E, Heim D, Stoyanov E, Harari-Steinfeld R, Steinfeld I, Pappo O, Perlman TS, Nachmansson N, Rivkin L, Olam D, Abramovitch R, Wege H, Galun E, et al. Specific genomic and transcriptomic aberrations in tumors induced by partial hepatectomy of a chronically inflamed murine liver. Oncotarget. 2014; 5(21):10318-10331.
26. Iannelli F, Collino A, Sinha S, Radaelli E, Nicoli P, D'Antiga L, Sonzogni A, Faivre J, Annick Buendia M, Sturm E, Thompson RJ, Knisely AS, Natoli G, et al. Massive gene amplification drives paediatric hepatocellular carcinoma caused by bile salt export pump deficiency. Nat Commun. 2014; 5:3850.
27. Kohli RM and Zhang Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature. 2013; 502(7472):472-479.
28. Ludwig G, Nejman D, Hecht M, Orlanski S, Abu-Remaileh M, Yanuka O, Sandler O, Marx A, Roberts D, Benvenisty N, Bergman Y, Mendelsohn M and Cedar H. Aberrant DNA methylation in ES cells. PLoS One. 2014; 9(5):e96090.
29. Miyaoka Y and Miyajima A. To divide or not to divide:revisiting liver regeneration. Cell Div. 2013; 8(1):8.
30. Backdahl L, Bushell A and Beck S. Inflammatory signalling as mediator of epigenetic modulation in tissue-specific chronic inflammation. Int J Biochem Cell Biol. 2009; 41(1):176-184.
31. Martin M and Herceg Z. From hepatitis to hepatocellular carcinoma: a proposed model for cross-talk between inflammation and epigenetic mechanisms. Genome Med. 2012; 4(1):8.
32. Bergman Y and Cedar H. DNA methylation dynamics in health and disease. Nat Struct Mol Biol. 2013; 20(3):274-281.
33. Nejman D, Straussman R, Steinfeld I, Ruvolo M, Roberts D, Yakhini Z and Cedar H. Molecular rules governing de novo methylation in cancer. Cancer Res. 2014; 74(5):1475-1483.
34. Takasugi M. Progressive age-dependent DNA methylation changes start before adulthood in mouse tissues. Mech Ageing Dev. 2011; 132(1-2):65-71.
35. Li W and Liu M. Distribution of 5-hydroxymethylcytosine in different human tissues. J Nucleic Acids. 2011; 2011:870726.
36. Yang H, Liu Y, Bai F, Zhang JY, Ma SH, Liu J, Xu ZD, Zhu HG, Ling ZQ, Ye D, Guan KL and Xiong Y. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene. 2013; 32(5):663-669.
37. Liu C, Liu L, Chen X, Shen J, Shan J, Xu Y, Yang Z, Wu L, Xia F, Bie P, Cui Y, Bian XW and Qian C. Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1. PLoS One. 2013; 8(5):e62828.
38. Jangiam W, Tungjai M and Rithidech KN. Induction of chronic oxidative stress, chronic inflammation and aberrant patterns of DNA methylation in the liver of titaniumexposed CBA/CaJ mice. Int J Radiat Biol. 2015:1-10.
39. Lian CG, Xu S, Guo W, Yan J, Frank MY, Liu R, Liu C, Chen Y, Murphy GF and Chen T. Decrease of 5-hydroxymethylcytosine in rat liver with subchronic exposure to genotoxic carcinogens riddelliine and aristolochic acid. Mol Carcinog. 2014.
40. Hirose K, Shimoda N and Kikuchi Y. Transient reduction of 5-methylcytosine and 5-hydroxymethylcytosine is associated with active DNA demethylation during regeneration of zebrafish fin. Epigenetics. 2013; 8(9):899-906.
41. Ivanov M, Kals M, Kacevska M, Barragan I, Kasuga K, Rane A, Metspalu A, Milani L and Ingelman-Sundberg M. Ontogeny, distribution and potential roles of 5-hydroxymethylcytosine in human liver function. Genome Biol. 2013; 14(8):R83.
42. Tammen SA, Dolnikowski GG, Ausman LM, Liu Z, Kim KC, Friso S and Choi SW. Aging alters hepatic DNA hydroxymethylation, as measured by liquid chromatography/mass spectrometry. J Cancer Prev. 2014; 19(4):301-308.
43. Liu WR, Tian MX, Jin L, Yang LX, Ding ZB, Shen YH, Peng YF, Zhou J, Qiu SJ, Dai Z, Fan J and Shi YH. High expression of 5-hydroxymethylcytosine and isocitrate dehydrogenase 2 is associated with favorable prognosis after curative resection of hepatocellular carcinoma. J Exp Clin Cancer Res. 2014; 33:32.
44. Killian JK, Kim SY, Miettinen M, Smith C, Merino M, Tsokos M, Quezado M, Smith WI, Jr., Jahromi MS, Xekouki P, Szarek E, Walker RL, Lasota J, et al. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov. 2013; 3(6):648-657.
45. Lou S, Lee HM, Qin H, Li JW, Gao Z, Liu X, Chan LL, Lam V, So WY, Wang Y, Lok S, Wang J, Ma R, et al. Whole-genome bisulfite sequencing of multiple individuals reveals complementary roles of promoter and gene body methylation in transcriptional regulation. Genome Biol. 2014; 15(7):408.
46. Sproul D, Kitchen RR, Nestor CE, Dixon JM, Sims AH, Harrison DJ, Ramsahoye BH and Meehan RR. Tissue of origin determines cancer-associated CpG island promoter hypermethylation patterns. Genome Biol. 2012; 13(10):R84.
47. Lee HC, Li SH, Lin JC, Wu CC, Yeh DC and Wei YH. Somatic mutations in the D-loop and decrease in the copy number of mitochondrial DNA in human hepatocellular carcinoma. Mutat Res. 2004; 547(1-2):71-78.
48. Fukushima S, Honda K, Awane M, Yamamoto E, Takeda R, Kaneko I, Tanaka A, Morimoto T, Tanaka K and Yamaoka Y. The frequency of 4977 base pair deletion of mitochondrial DNA in various types of liver disease and in normal liver. Hepatology. 1995; 21(6):1547-1551.
49. Kotake K, Nonami T, Kurokawa T, Nakao A, Murakami T and Shimomura Y. Human livers with cirrhosis and hepatocellular carcinoma have less mitochondrial DNA deletion than normal human livers. Life Sci. 1999; 64(19):1785-1791.
50. Diede SJ, Yao Z, Keyes CC, Tyler AE, Dey J, Hackett CS, Elsaesser K, Kemp CJ, Neiman PE, Weiss WA, Olson JM and Tapscott SJ. Fundamental differences in promoter CpG island DNA hypermethylation between human cancer and genetically engineered mouse models of cancer. Epigenetics. 2013; 8(12).
51. Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013; 14(10):R115.
52. Tsunedomi R, Ogawa Y, Iizuka N, Sakamoto K, Tamesa T, Moribe T and Oka M. The assessment of methylated BASP1 and SRD5A2 levels in the detection of early hepatocellular carcinoma. Int J Oncol. 2010; 36(1):205-212.
53. Iizuka N, Oka M, Sakaida I, Moribe T, Miura T, Kimura N, Tamatsukuri S, Ishitsuka H, Uchida K, Terai S, Yamashita S, Okita K, Sakata K, et al. Efficient detection of hepatocellular carcinoma by a hybrid blood test of epigenetic and classical protein markers. Clin Chim Acta. 2011; 412(1-2):152-158.
54. Song MA, Tiirikainen M, Kwee S, Okimoto G, Yu H and Wong LL. Elucidating the landscape of aberrant DNA methylation in hepatocellular carcinoma. PLoS One. 2013; 8(2):e55761.
55. Rougerie P, Largeteau Q, Megrelis L, Carrette F, Lejeune T, Toffali L, Rossi B, Zeghouf M, Cherfils J, Constantin G, Laudanna C, Bismuth G, Mangeney M, et al. Fam65b is a new transcriptional target of FOXO1 that regulates RhoA signaling for T lymphocyte migration. J Immunol. 2013; 190(2):748-755.
56. Gieling RG, Wallace K and Han YP. Interleukin-1 participates in the progression from liver injury to fibrosis. Am J Physiol Gastrointest Liver Physiol. 2009; 296(6):G1324-1331.
57. Latiano A, Palmieri O, Pastorelli L, Vecchi M, Pizarro TT, Bossa F, Merla G, Augello B, Latiano T, Corritore G, Settesoldi A, Valvano MR, D'Inca R, et al. Associations between genetic polymorphisms in IL-33, IL1R1 and risk for inflammatory bowel disease. PLoS One. 2013; 8(4):e62144.
58. Haimerl F, Erhardt A, Sass G and Tiegs G. Down-regulation of the de-ubiquitinating enzyme ubiquitin-specific protease 2 contributes to tumor necrosis factor-alpha-induced hepatocyte survival. J Biol Chem. 2009; 284(1):495-504.
59. Jin SG, Jiang Y, Qiu R, Rauch TA, Wang Y, Schackert G, Krex D, Lu Q and Pfeifer GP. 5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Cancer Res. 2011; 71(24):7360-7365.
60. Jeong KS and Lee S. Estimating the total mouse DNA methylation according to the B1 repetitive elements. Biochem Biophys Res Commun. 2005; 335(4):1211-1216.
61. Li LC and Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002; 18(11):1427-1431.
62. Mohn F, Weber M, Schubeler D and Roloff TC. Methylated DNA immunoprecipitation (MeDIP). Methods Mol Biol. 2009; 507:55-64.
63. Straussman R, Nejman D, Roberts D, Steinfeld I, Blum B, Benvenisty N, Simon I, Yakhini Z and Cedar H. Developmental programming of CpG island methylation profiles in the human genome. Nat Struct Mol Biol. 2009; 16(5):564-571.
64. Dawlaty MM, Breiling A, Le T, Raddatz G, Barrasa MI, Cheng AW, Gao Q, Powell BE, Li Z, Xu M, Faull KF, Lyko F and Jaenisch R. Combined deficiency of Tet1 and Tet2 causes epigenetic abnormalities but is compatible with postnatal development. Dev Cell. 2013; 24(3):310-323.